Abstract
Epidemiological studies have long associated circadian rhythm disruption (CRD)—often caused by shift work or chronic jet lag—with an increased risk of breast cancer. However, the precise mechanisms by which a disrupted internal clock influences mammary gland morphology and drives aggressive basal-like tumorigenesis have remained elusive. This study identifies the immune receptor LILRB4 as a critical mediator. Chronic CRD was found to disrupt mammary gland architecture, promote an immunosuppressive tumor microenvironment (TME), and accelerate lung metastasis by upregulating LILRB4 via a non-canonical WNT signaling pathway. Furthermore, targeted immunotherapy against LILRB4 was shown to reverse these effects, highlighting a novel therapeutic strategy for CRD-associated cancers.
Introduction
Aggressive triple-negative breast cancer (TNBC) is known for its poor prognosis and limited therapeutic options. While environmental factors like sleep disruption are linked to TNBC risk, the molecular "bridge" between systemic circadian disruption and local tumor progression has been a missing piece of the puzzle. This research investigates how chronic jet lag alters the mammary gland's physical structure and immune landscape, identifying LILRB4 as the key driver of this transformation.
Establishing the Circadian Disruption Model
To simulate chronic circadian disruption, researchers utilized a mouse model subjected to an 8-hour light phase advance every two days, mimicking permanent jet lag. This protocol successfully disrupted the rhythmic expression of core clock genes such as Bmal1, Per1, and Cry1 in mammary tissues.
Morphological Sabotage and Accelerated Tumorigenesis
One of the study's most striking findings was that CRD causes physical damage to the mammary gland even before tumors appear. Chronic disruption led to ductal hyperplasia and a breakdown of the protective myoepithelial cell layer. Quantitatively, CRD mice showed a significant reduction in mammary branching and terminal end buds, paired with a sharp increase in cellular proliferation (Ki67+ cells).
In genetically engineered mouse models (GEMM) of aggressive breast cancer, these morphological changes translated to faster tumor initiation. Tumors in CRD-exposed mice appeared at 18 weeks, compared to 22 weeks in control mice on a normal light/dark cycle. Furthermore, CRD significantly increased the metastatic burden in the lungs.
Turning Tumors "Cold": The Role of LILRB4
Using single-cell RNA sequencing (scRNA-seq), the team discovered that CRD shifts the tumor microenvironment from an immune-active ("hot") state to an immunosuppressive ("cold") state. This shift is characterized by an increase in M2-like macrophages and Regulatory T cells (Tregs), which protect the tumor from immune attack.
Central to this process is LILRB4 (Leukocyte Immunoglobulin-Like Receptor B4). The study found that CRD upregulates LILRB4, which in turn activates a non-canonical WNT signaling pathway (involving pJNK and c-FOS). This pathway promotes the expansion of cancer stem cells and the recruitment of immunosuppressive cells.
Therapeutic Potential
The researchers tested whether blocking LILRB4 could mitigate the effects of circadian disruption. Treatment with an anti-LILRB4 antibody in CRD mice successfully:
- Reduced the number of lung metastatic foci.
- Inhibited the immunosuppressive Treg population.
- Restored the activity of "killer" CD8+ T cells.
These results suggest that LILRB4-targeted immunotherapy could be a powerful tool for treating patients whose cancers are driven or exacerbated by circadian disruption.
Conclusion
This study establishes LILRB4 as a definitive link between a broken internal clock and aggressive mammary tumorigenesis. By identifying the LILRB4-WNT axis, the research provides both a molecular explanation for epidemiological observations and a promising new therapeutic target to combat the metastatic spread of breast cancer in the context of modern, sleep-disrupted lifestyles.
Reference: Ogunlusi, O., Sarkar, M., et al. LILRB4 regulates circadian disruption-induced mammary tumorigenesis via non-canonical WNT signaling pathway. Oncogene (2025).
Summary updated